A two-sided evaluation of benefit and harm from antithrombotic treatment in atrial fibrillation: Balancing clinical application and statistical methodology

Peter Brønnum Nielsen; Flemming Skjøth

doi:10.1160/TH16-07-0523

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2016; 116(03): 405-406
DOI: 10.1160/TH16-07-0523

Invited Editorial Focus

Schattauer GmbH

A two-sided evaluation of benefit and harm from antithrombotic treatment in atrial fibrillation: Balancing clinical application and statistical methodology

Peter Brønnum Nielsen

¹Department of Cardiology, Aalborg University Hospital, Denmark

²Aalborg Thrombosis Research Unit, Faculty of Health, Aalborg University, Denmark

,

Flemming Skjøth

²Aalborg Thrombosis Research Unit, Faculty of Health, Aalborg University, Denmark

³Unit for Clinical Biostatistics and Bioinformatics, Aalborg University Hospital, Denmark

› Author Affiliations

Abstract

Full Text

References

References
1 Wilson MR, Parakramawansha R, Quinn TJ. et al. Quality and predictors of anticoagulant control with vitamin K antagonist for stroke prevention in atrial fibrillation. Thromb Haemost 2016; 116: 578-580.
2 Blann AD, Skjøth F, Rasmussen LH. et al. Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost 2015; 114: 403-409.
3 Skjøth F, Larsen TB, Rasmussen LH. et al. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost 2014; 111: 1-8.
4 Villines TC, Schnee J, Fraeman K. et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost 2015; 114: 1290-1298.
5 Seeger JD, Bykov K, Bartels DB. et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost 2015; 114: 1277-1289.
6 Michalski F, Tittl L, Werth S. et al. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry. Thromb Haemost 2015; 114: 1076-1084.
7 Lane DA, Lip GYH.. Patient's values and preferences for stroke prevention in atrial fibrillation: Balancing stroke and bleeding risk with oral anti-coagulation. Thromb Haemost; 2014; 111: 381-383.
8 Olesen JB, Torp-Pedersen C.. Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc ≥1, or higher?. Thromb Haemost 2015; 113: 1165-1169.
9 Nielsen PB, Chao T-F.. The risks of risk scores for stroke risk assessment in atrial fibrillation. Thromb Haemost 2015; 113: 1170-1173.
10 Guo Y, Wang H, Tian Y. et al. Multiple risk factors and ischaemic stroke in the elderly Asian population with and without atrial fibrillation. An analysis of 425,600 Chinese individuals without prior stroke. Thromb Haemost 2016; 115: 184-192.
11 Philippart R, Brunet-Bernard A, Clementy N. et al. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project. Thromb Haemost 2016; 115: 1056-1063.
12 Paciaroni M, Agnelli G, Ageno W. et al. Timing of anticoagulation therapy in patients with acute is-chaemic stroke and atrial fibrillation. Thromb Haemost 2016; 116: 410-416.
13 Martinez C, Katholing A, Wallenhorst C. et al. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost 2016; 115: 31-39.
14 Singer DE, Chang Y, Fang MC. et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305.
15 Connolly SJ, Eikelboom JW, Ng J. et al. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med 2011; 155: 579-586.
16 Lip GYH, Skjøth F, Nielsen PB. et al. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. Thromb Haemost 2015; 114: 826-834.
17 Kittelson J, Goldenberg N, Kessler C. et al. Bivariate Evaluation of Thromboembolism and Bleeding In Clinical Trials of Anticoagulants in Patients with Atrial Fibrillation. Thromb Haemost 2016; 544-553.
18 Fauchier L, Clementy N, Bisson A. et al. Should Atrial Fibrillation Patients With Only 1 Non-gender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated?. Stroke 2016; 47: 1831-1836.
19 Nielsen PB, Larsen TB, Skjøth F. et al. Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. Sci Rep 2016; 6: 27410.